BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 17267163)

  • 1. 99mTc-sestamibi radio-guided surgery of loco-regional 131Iodine-negative recurrent thyroid cancer.
    Rubello D; Salvatori M; Casara D; Piotto A; Toniato A; Gross MD; Al-Nahhas A; Muzzio PC; Pelizzo MR
    Eur J Surg Oncol; 2007 Sep; 33(7):902-6. PubMed ID: 17267163
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The use of non-specific tracers in the follow up of differentiated thyroid cancer: results with Tc-99m tetrofosmin whole body scintigraphy.
    Lind P; Gallowitsch HJ
    Acta Med Austriaca; 1996; 23(1-2):69-75. PubMed ID: 8767519
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of technetium-99m methoxyisobutylisonitrile scintigraphy in the planning of therapy and follow-up of patients with differentiated thyroid carcinoma after surgery.
    Rubello D; Mazzarotto R; Casara D
    Eur J Nucl Med; 2000 Apr; 27(4):431-40. PubMed ID: 10805117
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 99mTc-sestamibi and 131I whole-body scintigraphy and initial serum thyroglobulin in the management of differentiated thyroid carcinoma.
    Ng DC; Sundram FX; Sin AE
    J Nucl Med; 2000 Apr; 41(4):631-5. PubMed ID: 10768563
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Is diagnostic iodine-131 scanning with recombinant human TSH useful in the follow-up of differentiated thyroid cancer after thyroid ablation?
    Mazzaferri EL; Kloos RT
    J Clin Endocrinol Metab; 2002 Apr; 87(4):1490-8. PubMed ID: 11932270
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Thyroglobulin and low-dose iodine-131 and technetium-99m-tetrofosmin whole-body scintigraphy in differentiated thyroid carcinoma.
    Gallowitsch HJ; Mikosch P; Kresnik E; Unterweger O; Gomez I; Lind P
    J Nucl Med; 1998 May; 39(5):870-5. PubMed ID: 9591591
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tc-99m-tetrofosmin scintigraphy: an alternative scintigraphic method for following up differentiated thyroid carcinoma--preliminary results.
    Gallowitsch HJ; Kresnik E; Mikosch P; Pipam W; Gomez I; Lind P
    Nuklearmedizin; 1996 Dec; 35(6):230-5. PubMed ID: 8976503
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Technetium-99m methoxyisobutylisonitrile imaging in the follow-up of differentiated thyroid carcinoma.
    Sriprapaporn J; Toopmongkol C; Satayaban B; Chantamoon N
    Ann Acad Med Singap; 2002 Mar; 31(2):195-8. PubMed ID: 11957557
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Whole-body Tc-99m sestamibi scintigraphy in the follow-up of differentiated thyroid carcinoma.
    Almeida-Filho P; Ravizzini GC; Almeida C; Borges-Neto S
    Clin Nucl Med; 2000 Jun; 25(6):443-6. PubMed ID: 10836693
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical approach in patients with metastatic differentiated thyroid carcinoma and negative 131I whole body scintigraphy: importance of 99mTc MIBI scan combined with high resolution neck ultrasonography.
    Casara D; Rubello D; Saladini G; Mazzarotto R; Sotti G; Tomasella G; Pelizzo MR
    Tumori; 1999; 85(2):122-7. PubMed ID: 10363078
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Technetium-99m-sestamibi uptake by recurrent Hurthle cell carcinoma of the thyroid.
    Balon HR; Fink-BennetT D; Stoffer SS
    J Nucl Med; 1992 Jul; 33(7):1393-5. PubMed ID: 1535374
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sensitivity of 123I whole-body scan and thyroglobulin in the detection of metastases or recurrent differentiated thyroid cancer.
    de Geus-Oei LF; Oei HY; Hennemann G; Krenning EP
    Eur J Nucl Med Mol Imaging; 2002 Jun; 29(6):768-74. PubMed ID: 12029550
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of 99mTc-methoxyisobutyl isonitrile and 201Tl scintigraphy for detection of residual thyroid cancer after 131I ablative therapy.
    Seabold JE; Gurll N; Schurrer ME; Aktay R; Kirchner PT
    J Nucl Med; 1999 Sep; 40(9):1434-40. PubMed ID: 10492361
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of indium-111 pentetreotide somatostatin receptor scintigraphy to detect recurrent thyroid carcinoma in patients with negative radioiodine scintigraphy.
    Valli N; Catargi B; Ronci N; Leccia F; Guyot M; Roger P; Ducassou D; Tabarin A
    Thyroid; 1999 Jun; 9(6):583-9. PubMed ID: 10411121
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nuclear medicine imaging procedures in differentiated thyroid carcinoma patients with negative iodine scan.
    Rubello D; Saladini G; Carpi A; Casara D
    Biomed Pharmacother; 2000 Jul; 54(6):337-44. PubMed ID: 10989970
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gamma probe-guided resection and scanning with TC-99m MIBI of a local recurrence of follicular thyroid carcinoma.
    Boz A; Arici C; Güngör F; Yildiz A; Colak T; Karayalçin B
    Clin Nucl Med; 2001 Oct; 26(10):820-2. PubMed ID: 11564916
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diagnostic value of technetium-99m methoxyisobutyl isonitrile (99mTc-MIBI) scintigraphy in detecting thyroid cancer metastases: a critical evaluation.
    Alam MS; Kasagi K; Misaki T; Miyamoto S; Iwata M; Iida Y; Konishi J
    Thyroid; 1998 Dec; 8(12):1091-100. PubMed ID: 9920363
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Follow-up of differentiated thyroid cancer: what is the value of FDG and sestamibi in the diagnostic algorithm?
    Dietlein M; Scheidhauer K; Voth E; Theissen P; Schicha H
    Nuklearmedizin; 1998 Jan; 37(1):12-7. PubMed ID: 9467164
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Outcome of differentiated thyroid cancer with detectable serum Tg and negative diagnostic (131)I whole body scan: comparison of patients treated with high (131)I activities versus untreated patients.
    Pacini F; Agate L; Elisei R; Capezzone M; Ceccarelli C; Lippi F; Molinaro E; Pinchera A
    J Clin Endocrinol Metab; 2001 Sep; 86(9):4092-7. PubMed ID: 11549631
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Is diagnostic iodine-131 scanning useful after total thyroid ablation for differentiated thyroid cancer?
    Cailleux AF; Baudin E; Travagli JP; Ricard M; Schlumberger M
    J Clin Endocrinol Metab; 2000 Jan; 85(1):175-8. PubMed ID: 10634383
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.